CR20250060A - Anticuerpos anti monometil auristatina y fragmentos de anticuerpos. - Google Patents

Anticuerpos anti monometil auristatina y fragmentos de anticuerpos.

Info

Publication number
CR20250060A
CR20250060A CR20250060A CR20250060A CR20250060A CR 20250060 A CR20250060 A CR 20250060A CR 20250060 A CR20250060 A CR 20250060A CR 20250060 A CR20250060 A CR 20250060A CR 20250060 A CR20250060 A CR 20250060A
Authority
CR
Costa Rica
Prior art keywords
antibodies
antibody fragments
adc
payload
monomethyl auristatin
Prior art date
Application number
CR20250060A
Other languages
English (en)
Inventor
M Bordeau Brandon
Ryan Polli Joseph
Duc NGUYEN Toan
P Balthasar Joseph
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of CR20250060A publication Critical patent/CR20250060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Se proporcionan composiciones y métodos para reducir la toxicidad no objetivo de los conjugados anticuerpo-fármaco (ADC). Las composiciones comprenden un ADC y un agente dirigido al fármaco (carga útil) administrado por el ADC o derivado del mismo. El ADC y el agente dirigido a la carga útil pueden administrarse juntos o por separado en el tratamiento de diversas afecciones (como tumores) mediante ADCs. Ejemplos de agentes dirigidos a la carga útil incluyen anticuerpos, fragmentos o modificaciones de los mismos.
CR20250060A 2022-08-24 2023-08-24 Anticuerpos anti monometil auristatina y fragmentos de anticuerpos. CR20250060A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263373367P 2022-08-24 2022-08-24
US202363520689P 2023-08-21 2023-08-21
PCT/US2023/072852 WO2024044709A2 (en) 2022-08-24 2023-08-24 Anti-monomethyl auristatin antibodies and antibody fragments

Publications (1)

Publication Number Publication Date
CR20250060A true CR20250060A (es) 2025-03-18

Family

ID=90014109

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250060A CR20250060A (es) 2022-08-24 2023-08-24 Anticuerpos anti monometil auristatina y fragmentos de anticuerpos.

Country Status (14)

Country Link
EP (1) EP4577568A2 (es)
JP (1) JP2025528390A (es)
KR (1) KR20250060232A (es)
CN (1) CN120035610A (es)
AU (1) AU2023329378A1 (es)
CA (1) CA3265572A1 (es)
CO (1) CO2025002048A2 (es)
CR (1) CR20250060A (es)
DO (1) DOP2025000040A (es)
GE (1) GEAP202516711A (es)
IL (1) IL319054A (es)
MX (1) MX2025002127A (es)
PE (1) PE20251523A1 (es)
WO (1) WO2024044709A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025043019A1 (en) * 2023-08-21 2025-02-27 The Research Foundation For The State University Of New York Slc4a1 (band 3) binding single domain antibodies for increased blood retention
AU2025282358A1 (en) 2024-06-05 2026-01-29 Remegen Co., Ltd. Ligand-drug conjugate having free payload recovery unit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2018177371A1 (en) * 2017-03-29 2018-10-04 Taipei Medical University Antigen-specific t cells and uses thereof
AU2018370279B2 (en) * 2017-11-17 2022-11-03 Abl Bio Inc. Antibodies to a-synuclein and uses thereof
CN109912684A (zh) * 2019-03-08 2019-06-21 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体
EP4069312A4 (en) * 2019-12-04 2024-03-27 The Research Foundation for the State University of New York COMPOSITIONS AND METHODS FOR REDUCING OFF-TARGET TOXICITY OF ANTIBODY-DRUG CONJUGATES

Also Published As

Publication number Publication date
CO2025002048A2 (es) 2025-07-17
KR20250060232A (ko) 2025-05-07
PE20251523A1 (es) 2025-06-05
WO2024044709A2 (en) 2024-02-29
AU2023329378A1 (en) 2025-03-06
JP2025528390A (ja) 2025-08-28
DOP2025000040A (es) 2025-06-15
EP4577568A2 (en) 2025-07-02
GEAP202516711A (en) 2025-06-10
MX2025002127A (es) 2025-05-02
CN120035610A (zh) 2025-05-23
CA3265572A1 (en) 2024-02-29
WO2024044709A3 (en) 2024-04-04
IL319054A (en) 2025-04-01

Similar Documents

Publication Publication Date Title
CO2025002048A2 (es) Anticuerpos anti monometil auristatina y fragmentos de anticuerpos
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
MX2023001163A (es) Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo.
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
MX2023004032A (es) Terapias inmuno-oncologicas con conjugados de il-2.
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
MX2023015471A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos humanizados que eligen como blanco la proteina asociada al receptor activador de plasminogeno tipo uroquinasa (uparap).
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
PH12022553333A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
CL2025002617A1 (es) Conjugados anticuerpo-fármaco administrados por vía subcutánea para el uso en el tratamiento del cáncer
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
MX2025007523A (es) Conjugados de anticuerpo-farmaco que eligen como blanco al receptor uparap que comprenden derivados de exatecan
CL2025001214A1 (es) Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
CO2021016982A2 (es) Métodos de uso de una construcción biespecífica de unión al antígeno dirigida a her2 para el tratamiento de cánceres de las vías biliares
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
CO2025017899A2 (es) Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine
AR130809A1 (es) Conjugados de anticuerpo y fármaco que se dirigen a napi2b y métodos de uso
AR134425A1 (es) Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
CO2025006752A2 (es) Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
CO2025008795A2 (es) Agonistas de tlr7 y conjugatos anticuerpo-fármaco de los mismos
WO2025078881A3 (en) Anti-claudin 18.2 antibody drug conjugates comprising topoisomerase i inhibitor and uses thereof